Search

everythinglearnresearchcommunity

for

Search:↓

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A user with early-stage diffuse hair thinning asked for long-term success stories using treatments like finasteride, minoxidil, and RU58841. One person regained most of their hair after 22 months on finasteride and minoxidil, while another saw significant improvement with oral minoxidil after trying various treatments over many years.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses identifying permanent hair loss and includes treatments like microneedling and biotin vitamins. The user is unsure whether the reduction in wispy hairs is due to hair revitalization or loss.

A user from Iran reports hair growth in bald spots after using a domestic tonic containing Anageline, Trichogen, Aminexil, Caffeine, Saw Palmetto, and B vitamins, alongside Finasteride, but without Minoxidil. They prefer the tonic over Minoxidil as it doesn't make their hair greasy or cause hair fall.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses the effectiveness of an eyebrow serum containing Myristoyl Pentapeptide and Biotinoyl Tripeptide for hair growth. The user seeks information on other topical products with similar peptides for hair growth.

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

The conversation discusses future hair loss treatments, with mentions of dutasteride potentially gaining FDA approval and increased popularity. Skepticism remains about significant advancements due to limited funding and reliance on cosmetic companies.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

The conversation humorously suggests that elites with full hair are suppressing a hair loss cure to maintain their dating advantage. It mentions treatments like hair systems, hair transplants, and medications such as Minoxidil and finasteride.

A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.

The user discusses their long struggle with hair loss, considering various treatments like hair transplants, hair systems, and natural methods such as micro-needling, vitamin supplements, and a healthy lifestyle. They express concerns about side effects from drugs like finasteride and ultimately lean towards using a hair system for better appearance and confidence.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The conversation is about using GHK-CU peptide for hair regrowth. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments for hair loss.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

A user who was losing their hair and found an effective solution; they asked for opinions on it and discussed treatments such as Minoxidil, Finasteride, and RU58841, as well as SMP.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Reverse conditioning can help achieve volume and well-conditioned hair for those with diffuse thinning. The user also mentioned using dutasteride.